

ERRATUM

Open Access



Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

Jeffrey N. Miner^{1*}, Philip K. Tan¹, David Hyndman¹, Sha Liu¹, Cory Iverson¹, Payal Nanavati¹, David T. Hagerty¹, Kimberly Manhard¹, Zancong Shen¹, Jean-Luc Girardet¹, Li-Tain Yeh¹, Robert Terkeltaub² and Barry Quart¹

Erratum

Unfortunately, after publication of this article [1], it was noticed that the name of Jeffrey N. Miner was captured incorrectly during the production process. The middle initial 'N' was missing from the list. The corrected author list can be seen above and the original article has been updated to correct this error.

Author details

¹Ardea Biosciences, Inc., 9390 Towne Centre Drive, San Diego, CA 92121, USA. ²University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

Received: 7 October 2016 Accepted: 7 October 2016

Published online: 12 October 2016

Reference

1. Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet J-L, Yeh L-T, Terkeltaub R, Quart B. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. *Arthritis Res Ther*. 2016;18:214. doi:10.1186/s13075-016-1107-x.

* Correspondence: jminer@ardeabio.com

¹Ardea Biosciences, Inc., 9390 Towne Centre Drive, San Diego, CA 92121, USA
Full list of author information is available at the end of the article